Skip to main content
Premium Trial:

Request an Annual Quote

LGC to Distribute AutoGen Sample Prep Platforms

NEW YORK (GenomeWeb) – AutoGen today said that it has signed a distribution agreement with Hoddesdon, UK-based LGC.

Under the deal, LGC will distribute Holliston, Mass.-based AutoGen's FlexStar, Arrow, and QuickGene platforms in Europe, the Middle East, and Africa. Specific terms of the agreement were not disclosed.

The FlexStar is a fully automated platform for DNA extraction and isolation, while the Arrow uses paramagnetic bead technology for automated DNA and RNA extraction. The QuickGene platform consists of three models that are also used for DNA and RNA extraction and isolation.

"The combination of AutoGen's reliable nucleic acid systems and LGC's market presence and expertise in genomics will make a great team to serve both our new and existing customers in the European market," AutoGen CEO Bob Sullivan said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.